kentucky glp-1 pancreatitis class action Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology Does Semaglutide Cause Pancreatitis? Evidence

As clinical data and public discussion intersect, these launches are rewriting every rule in pharma marketing commanding broad consumer attention, setting new standards for adoption speed, and (perhaps most importantly) reshaping eXpectations around how life sciences brands engage, educate, and []

This is the evidence-based guide you've been searching for

Korean pharmaceutical and biotech companies are heading to the American Diabetes Association (ADA) 2026 Scientific Sessions with obesity and metabolic disease pipelines that reflect the industry's shift beyond simple weight loss toward muscle preservation, management of metabolic comorbidities and m

Virta Health has released first-of-its-kind, peer-reviewed data demonstrating the companys approach to personalized nutrition therapy results in sustained weight loss after the discontinuation of glucagon-like peptide-1 receptor agonists, including Ozempic.

Clean, easy-to-read layout